- Home
- DXCM vs STE Comparison
DXCM vs STE Comparison
Compare DXCM & STE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXCM
- STE
- Stock Information
- Founded
- DXCM 1999
- STE 1985
- Country
- DXCM United States
- STE United States
- Employees
- DXCM N/A
- STE N/A
- Industry
- DXCM Medical/Dental Instruments
- STE Industrial Specialties
- Sector
- DXCM Health Care
- STE Health Care
- Exchange
- DXCM Nasdaq
- STE Nasdaq
- Market Cap
- DXCM 28.0B
- STE 22.1B
- IPO Year
- DXCM 2005
- STE 1992
- Fundamental
- Price
- DXCM $80.10
- STE $214.03
- Analyst Decision
- DXCM Buy
- STE Buy
- Analyst Count
- DXCM 17
- STE 6
- Target Price
- DXCM $98.00
- STE $253.00
- AVG Volume (30 Days)
- DXCM 3.6M
- STE 590.9K
- Earning Date
- DXCM 02-06-2025
- STE 02-05-2025
- Dividend Yield
- DXCM N/A
- STE 1.08%
- EPS Growth
- DXCM 83.21
- STE N/A
- EPS
- DXCM 1.67
- STE 4.37
- Revenue
- DXCM $3,954,000,000.00
- STE $5,325,525,000.00
- Revenue This Year
- DXCM $13.10
- STE $7.91
- Revenue Next Year
- DXCM $14.79
- STE $6.37
- P/E Ratio
- DXCM $48.26
- STE $48.17
- Revenue Growth
- DXCM 16.19
- STE 15.75
- 52 Week Low
- DXCM $62.34
- STE $197.82
- 52 Week High
- DXCM $142.00
- STE $248.24
- Technical
- Relative Strength Index (RSI)
- DXCM 63.91
- STE 31.35
- Support Level
- DXCM $77.33
- STE $214.35
- Resistance Level
- DXCM $82.26
- STE $219.30
- Average True Range (ATR)
- DXCM 2.38
- STE 4.19
- MACD
- DXCM 0.07
- STE -0.16
- Stochastic Oscillator
- DXCM 81.64
- STE 0.73
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About STE STERIS plc (Ireland)
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.